





Astrocytes Proteasomal Catabolism 
Alzheimer’s Disease (AD) is the most common form of 
dementia and is characterized by a progressive decline in cognition 
and everyday function. For decades, AD research has centered 
around the aggregation of amyloid and tau proteins. Evidence 
indicates that the biochemical and cellular phases of the disease are 
not entirely understood. There is a need for a better understanding 
of the underlying disease processes to allow for early detection and 
the ability to halt progression through more effective treatment 
options. Proteomics research is capable of providing much of the 
missing pieces when it comes to understanding the underlying 
disease processes of AD.
Recently, Johnson et al. developed a mass spectrometry 
pipeline utilizing tandem mass tag (TMT) technology which allowed 
for quantification of proteins in brains from control, asymptomatic, 
and symptomatic cases of AD. 
The goal of this project was to expand upon the data published 
from Johnson et al. by narrowing in on a comparison between 
asymptomatic AD and AD protein abundances. The presented 
findings arising from the computational analysis highlight interesting 
biological processes that may shed more light into the mechanism 
leading to disease progression in AD. Further study into these 
mechanisms in AD can help increase our understanding and lead to 
an eventual advancement in early intervention and better treatment 
options for AD.
Illustration of the yellow beta-amyloid plaques and the blue 
neurofibrillary tau tangles that disrupt neuron transmission and lead 
to neurodegeneration. 
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Gene Ontology Analysis
• Enriched activation, development, and differentiation 
processes of Astrocytes in AD
• Evidence points to astrocytes as an important biomarker
• Potential biomarker that can successfully diagnose, 
differentiate, or predict the rate of decline between AD disease 
stages
• Next Steps: Explore the relationship of astrocyte processes 
comparing asymptomatic AD and cognitively healthy cases to 
be able to understand astrocytes as biomarkers for the rate of 
cognitive decline 
• Enriched ubiquitin-independent protein catabolic processes in 
AD
• Process may be enriched for several reasons
• Over-compensation in degradation pathways to attempt 
homeostasis as proteins aggregate in AD
• Lack of sufficient ubiquitin-dependent protein catabolism
• Normal tau degradation does not require ubiquitin
• Next Steps: Investigate proteasome interaction in AD to gain 
insight which may prove helpful in developing treatment 
options
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Figure 3. Highlighted proteins are in significant abundance 
when comparing asymptomatic AD and AD. 
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• Proteomics research allows for a better understanding of the 
underlying disease process of AD. 
• Biological processes related to astrocyte activation, development, 
and differentiation are enriched in AD compared to asymptomatic 
AD.
• Ubiquitin-independent protein catabolic processes are also 
enriched in AD compared to asymptomatic AD.
• Comparing the protein abundance between two stages of the 
disease provides a way for early intervention methods to be 
discovered and better treatment options developed. 
• Future Step: Incorporate findings comparing between control and 
asymptomatic data to better understand the underlying disease 
processes. 
Figure 1. Highlighted proteins are enriched in AD compared 
to asymptomatic AD and are involved in the activation, 
development, and differentiation of astrocytes.
Figure 2. Highlighted proteins are enriched in AD compared to 
asymptomatic AD and are alpha subunits of the proteasome 
playing a role in protein catabolism which in this case is 
ubiquitin-independent. 
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• Collection and Preparation of Samples
• TMT Pipeline and Protein Quantification
• Published Public Data
Investigation of Proteomics Data
• Using R Software and R Studio 
• Filtered Data to Significant P-Values
• Filtered Significant P-Values to Significant P-Values for the 
Difference of Asymptomatic AD – AD
• Filtered to Positive and Negative Differences in the P-Values of 
Asymptomatic AD – AD 
• Created a Volcano Plot to Display Protein Abundance Findings
• Ran a Gene Ontology (GO) Term Analysis of the Significant 
Proteins
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